- Home
- HOWL vs KRRO Comparison
HOWL vs KRRO Comparison
Compare HOWL & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- KRRO
- Stock Information
- Founded
- HOWL 2017
- KRRO 2014
- Country
- HOWL United States
- KRRO United States
- Employees
- HOWL N/A
- KRRO N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- KRRO Health Care
- Exchange
- HOWL Nasdaq
- KRRO Nasdaq
- Market Cap
- HOWL 64.5M
- KRRO 58.6M
- IPO Year
- HOWL 2021
- KRRO 2019
- Fundamental
- Price
- HOWL $0.99
- KRRO $5.55
- Analyst Decision
- HOWL Strong Buy
- KRRO Buy
- Analyst Count
- HOWL 5
- KRRO 10
- Target Price
- HOWL $7.00
- KRRO $74.17
- AVG Volume (30 Days)
- HOWL 670.5K
- KRRO 1.0M
- Earning Date
- HOWL 11-04-2025
- KRRO 11-12-2025
- Dividend Yield
- HOWL N/A
- KRRO N/A
- EPS Growth
- HOWL N/A
- KRRO N/A
- EPS
- HOWL N/A
- KRRO N/A
- Revenue
- HOWL N/A
- KRRO $7,371,000.00
- Revenue This Year
- HOWL N/A
- KRRO $116.91
- Revenue Next Year
- HOWL N/A
- KRRO N/A
- P/E Ratio
- HOWL N/A
- KRRO N/A
- Revenue Growth
- HOWL N/A
- KRRO N/A
- 52 Week Low
- HOWL $0.60
- KRRO $5.42
- 52 Week High
- HOWL $2.38
- KRRO $56.69
- Technical
- Relative Strength Index (RSI)
- HOWL 37.92
- KRRO 20.89
- Support Level
- HOWL $0.80
- KRRO $5.82
- Resistance Level
- HOWL $1.03
- KRRO $6.59
- Average True Range (ATR)
- HOWL 0.10
- KRRO 1.47
- MACD
- HOWL 0.01
- KRRO -1.22
- Stochastic Oscillator
- HOWL 43.93
- KRRO 0.48
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.